National Institute on Alcohol Abuse and Alcoholism (NIAAA)
946
151
196
627
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
5.7%
54 terminated/withdrawn out of 946 trials
92.1%
+5.5% vs industry average
8%
80 trials in Phase 3/4
52%
326 of 627 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (946)
Effect of Acute Alcohol Intoxication on Neural Processes During Decisions to Engage in HIV Risk Behaviors
Role: lead
Personalizing Treatment Delivery
Role: collaborator
Pregnenolone Treatment for Alcohol Use Disorder and Major Depressive Disorder
Role: collaborator
Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness
Role: lead
Brain Inflammation and Function in Alcoholism
Role: lead
Physical Activity for PLWH and Unhealthy Drinking
Role: collaborator
Telehealth for Pain and Unhealthy Drinking Among PLWH
Role: collaborator
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
Role: lead
SHARE Project Define
Role: collaborator
Reliability of the Human Brain Connectome
Role: lead
Nicotinic Receptor Genetic Variation and Alcohol Reward
Role: lead
PNF RCT to Decrease Alcohol Use and Increase HIV Prevention
Role: collaborator
Whole Selves User Testing and Feasibility Study
Role: collaborator
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
Role: collaborator
Understanding Pathways to Wellness and Recovery in Detroit - Digital Recovery Support Services
Role: collaborator
Development of an Alcohol, Cannabis, and Sexual Assault Risk Reduction Program for High Risk College Women
Role: collaborator
Exploring the Decision to Drink (More) Alcohol Following Manipulations of Stress and Social Context
Role: collaborator
Pomegranate Dietary Supplements in AUD and ALD
Role: collaborator
Computer-Assisted Self-Administration of Ethanol
Role: lead
Tirzepatide in MetALD
Role: lead